A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
Ella Naparstek,Reuven Or,Arnon Nagler,G. Cividalli,Dan Engelhard,Memet Aker,Z. Gimon,N. Manny,T. Sacks,Z. Tochner,Lola Weiss,Simcha Samuel,Chaim Brautbar,G. Hale,Herman Waldmann,Seth M. Steinberg,Shimon Slavin +16 more
TL;DR: The data suggest that in patients receiving marrow allografts depleted of T cells by Campath 1 monoclonal antibodies, rejection can be reduced by adequate pregrafting immunosuppression, and post‐transplant cell‐mediated immunotherapy (CMI) using donor's PBL may be beneficial.
Journal ArticleDOI
High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
Susan O'Brien,Gary J. Schiller,John Lister,Lloyd E. Damon,Stuart L. Goldberg,Walter E. Aulitzky,Dina Ben-Yehuda,Wendy Stock,Steven Coutre,Dan Douer,Leonard T. Heffner,Melissa C. Larson,Karen Seiter,Scott E. Smith,Sarit Assouline,Philip Kuriakose,Lori J. Maness,Arnon Nagler,Jacob M. Rowe,Markus Schaich,Ofer Shpilberg,Karen W.L. Yee,Guenter Schmieder,Jeffrey Silverman,Deborah A. Thomas,Steven R. Deitcher,Hagop M. Kantarjian +26 more
TL;DR: High-dose VSLI monotherapy resulted in meaningful clinical outcomes including durable responses and bridging to HCT in advanced ALL settings, and the toxicity profile of V SLI was predictable, manageable, and comparable to standard VCR despite the delivery of large, normally unachievable, individual and cumulative doses of VCR.
Journal ArticleDOI
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Guy Ledergor,Guy Ledergor,Assaf Weiner,Mor Zada,Shuang-Yin Wang,Yael C Cohen,Yael C Cohen,Moshe E. Gatt,Moshe E. Gatt,Nimrod Snir,Nimrod Snir,Hila Magen,Hila Magen,Maya Koren-Michowitz,Katrin Herzog-Tzarfati,Hadas Keren-Shaul,Chamutal Bornstein,Ron Rotkopf,Ido Yofe,Eyal David,Venkata Yellapantula,Sigalit Kay,Moshe Salai,Moshe Salai,Dina Ben Yehuda,Dina Ben Yehuda,Arnon Nagler,Arnon Nagler,Lev Shvidel,Lev Shvidel,Avi Orr-Urtreger,Avi Orr-Urtreger,Keren Bahar Halpern,Shalev Itzkovitz,Ola Landgren,Jesús F. San-Miguel,Bruno Paiva,Jonathan J Keats,Elli Papaemmanuil,Irit Avivi,Irit Avivi,Gabriel I. Barbash,Amos Tanay,Ido Amit +43 more
TL;DR: This work establishes single cell RNA sequencing for dissecting blood malignancies and devising detailed molecular characterization of tumor cells in symptomatic and asymptomatic patients, and identifies extensive subclonal structures for 10 of 29 individuals with multiple myeloma.
Journal ArticleDOI
Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.
TL;DR: The results of the human studies provide basis for using halofuginone treatment for dermal fibrosis and as a first step toward future treatment of internal organ involvement, an oral administration study was performed in which halofUGinone was well tolerated and plasma levels surpassed the predicted therapeutic exposure.
Journal ArticleDOI
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.
Charles Crawley,Richard Szydlo,Marc Lalancette,Andrea Bacigalupo,Andrzej Lange,Mats Brune,Gunnar Juliusson,Arnon Nagler,Alois Gratwohl,Jacob Passweg,Mieczysław Komarnicki,Antonin Vitek,Jiri Mayer,Axel R. Zander,Jorge Sierra,Alesssandro Rambaldi,Olle Ringdén,Dietger Niederwieser,Jane F. Apperley +18 more
TL;DR: Outcomes of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in 186 patients with chronic myeloid leukemia from the European Group for Blood and Marrow Transplantation (EBMT) are reported.